Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection
Open accessPublished version of a preprint
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The efficacy of virus-specific T cells in clearing pathogens involves a fine balance between antiviral and inflammatory features. SARS-CoV-2–specific T cells in individuals who clear SARS-CoV-2 without symptoms could reveal nonpathological yet protective characteristics. We longitudinally studied SARS-CoV-2–specific T cells in a cohort of asymptomatic (n = 85) and symptomatic (n = 75) COVID-19 patients after seroconversion. We quantified T cells reactive to structural proteins (M, NP, and Spike) using ELISpot and cytokine secretion in whole blood. Frequencies of SARS-CoV-2–specific T cells were similar between asymptomatic and symptomatic individuals, but the former showed an increased IFN-γ and IL-2 production. This was associated with a proportional secretion of IL-10 and proinflammatory cytokines (IL-6, TNF-α, and IL-1β) only in asymptomatic infection, while a disproportionate secretion of inflammatory cytokines was triggered by SARS-CoV-2–specific T cell activation in symptomatic individuals. Thus, asymptomatic SARS-CoV-2–infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using HLA class I and II predicted peptide “megapools,” circulating SARS-CoV-2-specific CD8+ and CD4+ T cells were identified in COVID-19 acute, mild and convalescent patients [110, 118-125].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [125]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dimensionality reduction for visualizing single-cell data using UMAP
Becht, E., McInnes, L., Healy, J., Dutertre, C.-A., Kwok, I. W. H., Ng, L. G., Ginhoux, F., & Newell, E. W. (2019) · Nature Biotechnology · doi:10.1038/nbt.4314 · Cited by 5,358
Self-citationGrifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
IL-10: The Master Regulator of Immunity to Infection
Couper, K. N., Blount, D. G., & Riley, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5771 · Cited by 2,223
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Self-citationSARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Self-citationRydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · cited 1×
“specific B cells progressively evolved after COVID-19 recovery due to the presence of SARS8 CoV-2 antigen in the small bowel (27), makes such hypothesis even more plausible.”
Background
Cited by
The T cell immune response against SARS-CoV-2
Moss, P. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,235
Single-cell multi-omics analysis of the immune response in COVID-19
Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID-19 BioResource Collaboration, Stephenson, E., Reynolds, G., Botting, R. A., Calero-Nieto, F. J., Morgan, M. D., Tuong, Z. K., Bach, K., Sungnak, W., Worlock, K. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01329-2 · Cited by 742
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
“This overlaps with the 0–800 SFC range (median 110) detected in a previous study describing S reactivity in symptomatic donors(49) and with the 20–110 range for 2–5 months’ symptomatic donors reported in a separate study.(50) VOC reactivity was observed for the S MPs in convalescent donors, with geomean IFN-g SFCs per…”
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Self-citationBorobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01420-3 · Cited by 350
SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., & Sette, A. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.010 · Cited by 314
“…(Chen et al., 2021; Ferretti et al., 2020; Gangaev et al., 2020; Habel et al., 2020; Joag et al., 2021; Kared et al., 2021; Keller et al., 2020; Le Bert et al., 2021, 2020; Lee et al., 2020; Mahajan et al., 2020; Mateus et al., 2020; Nelde et al., 2021; Nielsen et al., 2020; Peng et al., 2020;…”
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809244 · Cited by 299
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 269
Peluso, M. J., Deitchman, A. N., Torres, L., Iyer, N. S., Munter, S. E., Nixon, C. C., Donatelli, J., Thanh, C., Takahashi, S., Hakim, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109518 · Cited by 248
A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection
Augusto, D. G., Murdolo, L. D., Chatzileontiadou, D. S. M., Sabatino, J. J., Yusufali, T., Peyser, N. D., Butcher, X., Kizer, K., Guthrie, K., Murray, V. W., et al. (2023) · Nature · doi:10.1038/s41586-023-06331-x · Cited by 218
Jung, J. H., Rha, M.-S., Sa, M., Choi, H. K., Jeon, J. H., Seok, H., Park, D. W., Park, S.-H., Jeong, H. W., Choi, W. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24377-1 · Cited by 233
BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype
Guerrera, G., Picozza, M., D’Orso, S., Placido, R., Pirronello, M., Verdiani, A., Termine, A., Fabrizio, C., Giannessi, F., Sambucci, M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5344 · Cited by 234
Complement activation induces excessive T cell cytotoxicity in severe COVID-19
Georg, P., Astaburuaga-García, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T., Gäbel, C., Schneider, M., Streitz, M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.040 · Cited by 218
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity
Rodda, L. B., Morawski, P. A., Pruner, K. B., Fahning, M. L., Howard, C. A., Franko, N., Logue, J., Eggenberger, J., Stokes, C., Golez, I., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.018 · Cited by 195
“…differences, including the production of IL-10, have previously been described in SARS-CoV-2-specific CD4+ T cells from individuals that experienced different levels of COVID-19 severity, raising questions about how these cytokines may be involved in immune protection (Le Bert et al., 2021).”
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Kramvis, A., Chang, K.-M., Dandri, M., Farci, P., Glebe, D., Hu, J., Janssen, H. L. A., Lau, D. T. Y., Penicaud, C., Pollicino, T., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00649-z · Cited by 185
Wong, L.-Y. R., & Perlman, S. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00656-2 · Cited by 192
T Cell Responses to SARS-CoV-2
Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 186
Sherina, N., Piralla, A., Du, L., Wan, H., Kumagai-Braesch, M., Andréll, J., Braesch-Andersen, S., Cassaniti, I., Percivalle, E., Sarasini, A., et al. (2021) · Med · doi:10.1016/j.medj.2021.02.001 · Cited by 193
“The difference could be explained by the small number of samples included in our study, especially in the early disease phase, and/or the higher proportion of aged and severe patients in our cohort, as SARS-CoV2-specific T cell response may be stronger and persist longer in patients with severe disease due to a higher…”
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
Kalimuddin, S., Tham, C. Y. L., Qui, M., de Alwis, R., Sim, J. X. Y., Lim, J. M. E., Tan, H.-C., Syenina, A., Zhang, S. L., Le Bert, N., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.003 · Cited by 188
Self-citationAdaptive Immune Responses and Immunity to SARS-CoV-2
Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Ivkošić, I. E., & Parčina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848582 · Cited by 186
“However, SARS-CoV-2-specific T cells in asymptomatic patients were functionally superior to those detected in patients with symptoms, presuming that effective T cell response may be a part of an explanation and possible prediction of the severity of the disease (88).”
ResultSARS-CoV-2-specific T cells in infection and vaccination
Bertoletti, A., Le Bert, N., Qui, M., & Tan, A. T. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00743-3 · Cited by 159
“These marked differences were detected in terms of antibody levels and T cell responses after natural infection [17, 81, 82].”
BackgroundInfluentialSelf-citationHall, V. G., Ferreira, V. H., Ierullo, M., Ku, T., Marinelli, T. M., Majchrzak-Kita, B., Yousuf, A., Kulasingam, V., Humar, A., & Kumar, D. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16766 · Cited by 159
Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection
Adamo, S., Michler, J., Zurbuchen, Y., Cervia, C., Taeschler, P., Raeber, M. E., Sain, S. B., Nilsson, J., Moor, A. E., & Boyman, O. (2021) · Nature · doi:10.1038/s41586-021-04280-x · Cited by 163
Understanding T cell responses to COVID-19 is essential for informing public health strategies
Vardhana, S. A., Baldo, L., Morice, W. G., & Wherry, E. J. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo1303 · Cited by 153
Count on us: T cells in SARS-CoV-2 infection and vaccination
Kedzierska, K., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100562 · Cited by 134
“While a true T cell-based correlate of protection has not been defined, several studies implicate T cells as protective based on associations with symptoms and outcomes.(49,50) These studies identify robust T cell responses in subjects with asymptomatic disease or low symptomseverity.”
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.008 · Cited by 131
Self-citationLim, J. M. E., Tan, A. T., Bert, N. L., Hang, S. K., Low, J. G. H., & Bertoletti, A. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220780 · Cited by 120
Self-citationTan, A. T., Lim, J. M. E., Le Bert, N., Kunasegaran, K., Chia, A., Qui, M. D. C., Tan, N., Chia, W. N., de Alwis, R., Ying, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152379 · Cited by 109
Self-citationLozano-Ojalvo, D., Camara, C., Lopez-Granados, E., Nozal, P., del Pino-Molina, L., Bravo-Gallego, L. Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109570 · Cited by 114
“5% of the Spike protein and contain most of the SARS-CoV2 spike epitope published to date [10] were used as reported in [7]”
Self-citationNair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 114
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity
Qiu, Y., Su, Y., Xie, E., Cheng, H., Du, J., Xu, Y., Pan, X., Wang, Z., Chen, D. G., Hong, Z., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.003 · Cited by 111
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 112
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
Boyton, R. J., & Altmann, D. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00631-x · Cited by 107
Stellate ganglion block reduces symptoms of Long COVID: A case series
Liu, L. D., & Duricka, D. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577784 · Cited by 98
Arieta, C. M., Xie, Y. J., Rothenberg, D. A., Diao, H., Harjanto, D., Meda, S., Marquart, K., Koenitzer, B., Sciuto, T. E., Lobo, A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.007 · Cited by 91
Gittelman, R. M., Lavezzo, E., Snyder, T. M., Zahid, H. J., Carty, C. L., Elyanow, R., Dalai, S. C., Kirsch, I. R., Baldo, L., Manuto, L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151849 · Cited by 86
“T cell phenotype and function represent another important dimension that has been shown to impact disease severity (46).”
BackgroundDhawan, M. K., Rabaan, A. A., Alwarthan, S. M., Alhajri, M. M., Halwani, M. A., Alshengeti, A., Najim, M. A., Alwashmi, A. S. S., Alshehri, A. A., Alshamrani, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11030699 · Cited by 84
Niessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 84
“flammatory and regulatory (IL-10) cytokines (IL-6, IL-1β) [47,48].”
Functional SARS-CoV-2 cross-reactive CD4 + T cells established in early childhood decline with age
Humbert, M., Olofsson, A., Wullimann, D., Niessl, J., Hodcroft, E. B., Cai, C., Gao, Y., Sohlberg, E., Dyrdak, R., Mikaeloff, F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220320120 · Cited by 78
“In addition, the results are based on the enumeration of Th1 cytokines established to be produced by SARS-CoV-2-specific T cells, although other T cell profiles (e.g., production of IL-10) may also contribute to the age-dependent manifestation of COVID-19 (56).”
Duration of post–COVID-19 symptoms is associated with sustained SARS-CoV-2–specific immune responses
Files, J. K., Sarkar, S., Fram, T., Boppana, S., Sterrett, S., Qin, K., Bansal, A., Long, D. M., Sabbaj, S., Kobie, J. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151544 · Cited by 83
Lim, J. M. E., Hang, S. K., Hariharaputran, S., Chia, A., Tan, N., Lee, E. S., Chng, E., Lim, P. L., Young, B. E., Lye, D. C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100793 · Cited by 73
Self-citationZhang, H., Deng, S., Ren, L., Zheng, P., Hu, X., Jin, T., & Tan, X. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109708 · Cited by 71
“In a number of studies, cellular immunity has been shown to strongly correlate with disease outcome (Le Bert et al., 2021; Sattler et al., 2020; Sekine et al., 2020; Tan et al., 2021; Weiskopf et al., 2020), which indicates the importance of understanding the difference in cellular immunity for the…”
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 80
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 74
“However, a robust induction and functionally efficient SARS-CoV-2 T cell response to levels even superior to what is detectable in symptomatic COVID-19 patients has been found in recently infected asymptomatic individuals [23,30].”
BackgroundResultInfluentialSelf-citationGoletti, D., Petrone, L., Manissero, D., Bertoletti, A., Rao, S. N., Ndunda, N., Sette, A., & Nikolayevskyy, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.005 · Cited by 78
“Furthermore, an ELISpot-based IGRA using isolated peripheral blood mononuclear cells stimulated with peptides covering nucleoprotein, membrane and immunogenic regions of the SARSCoV-2 spike protein was able to differentiate SARS-CoV-2infected individuals with symptomatic or asymptomatic infection [19], and measure T-c…”
InfluentialSelf-citationNesamari, R., Omondi, M. A., Baguma, R., Höft, M. A., Ngomti, A., Nkayi, A. A., Besethi, A. S., Magugu, S. F. J., Mosala, P., Walters, A., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2023.12.003 · Cited by 72
Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients
Zhao, X.-N., You, Y., Cui, X.-M., Gao, H.-X., Wang, G.-L., Zhang, S.-B., Yao, L., Duan, L.-J., Zhu, K.-L., Wang, Y.-L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00753-7 · Cited by 61
T cell immune memory after covid-19 and vaccination
Wang, L., Nicols, A. R., Turtle, L. C. W., Richter, A. G., Duncan, C. J. A., Dunachie, S. J., Klenerman, P., & Payne, R. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000468 · Cited by 72
Self-citationRénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 69
Self-citationNelson, R. W., Chen, Y., Venezia, O. L., Majerus, R. M., Shin, D. S., MGH COVID-19 Collection & Processing Team, Carrington, M. N., Yu, X. G., Wesemann, D. R., Moon, J. J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9464 · Cited by 63
“Subsequent longitudinal analyses show relatively stable memory T and B cell responses over time following mild ( 5 – 7 ) and even asymptomatic ( 8 ) infections.”
InfluentialCurrent Vaccine Platforms in Enhancing T-Cell Response
Ura, T., Takeuchi, M., Kawagoe, T., Mizuki, N., Okuda, K., & Shimada, M. (2022) · Vaccines · doi:10.3390/vaccines10081367 · Cited by 60
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 60
“Interestingly, virus‐specific T cells appear to be functionally superior in asymptomatic individuals with a similar frequency of SARS‐CoV‐2‐specific T cells, but higher production of Th1 cytokines IFN‐γ and IL‐2 compared to symptomatic patients.(159) Pre‐existing SARS‐CoV‐2‐specific T cells were also detected in indiv…”
Scurr, M. J., Lippiatt, G., Capitani, L., Bentley, K., Lauder, S. N., Smart, K., Somerville, M. S., Rees, T., Stanton, R. J., Gallimore, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32985-8 · Cited by 55
The challenges of COVID‐19 Delta variant: Prevention and vaccine development
He, X., He, C., Hong, W., Zhang, K., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.95 · Cited by 55
Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease
Todorović‐Raković, N., & Whitfield, J. R. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155637 · Cited by 58
COVID-19: captures iron and generates reactive oxygen species to damage the human immune system
Wenzhong, L., & hualan, L. (2021) · Autoimmunity · doi:10.1080/08916934.2021.1913581 · Cited by 58
Asymptomatic COVID‐19: disease tolerance with efficient anti‐viral immunity against SARS‐CoV‐2
Chan, Y., Fong, S., Poh, C. M., Carissimo, G., Yeo, N. K., Amrun, S. N., Goh, Y. S., Lim, J., Xu, W., Chee, R. S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114045 · Cited by 56
“Samples with RIN of more than 6 were selected for the study. cDNA libraries were prepared by Smart-Seq v2 (Picelli et al, 2014), using a modification of the GlobinLock (GL) method (Krjut (cid:2) skov et al, 2016) to block transcription of globin mRNA.”
Self-citationKhoo, N. K. H., Lim, J. M. E., Gill, U. S., de Alwis, R., Tan, N., Toh, J. Z. N., Abbott, J. E., Usai, C., Ooi, E. E., Low, J. G. H., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.004 · Cited by 51
“[25] We detected 24 individuals who tested positive for at least one of the three peptide pools (membrane, NP1, and NP2).”
BackgroundSelf-citationAgrati, C., Bartolini, B., Bordoni, V., Locatelli, F., Capobianchi, M. R., Di, A., Castilletti, C., & Ippolito, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147871 · Cited by 53
“On the other hand, they might have a beneficial effect in the later, more severe, phase of COVID-19, preventing hyperinflammation and massive cytokine release that are, in fact, the main trigger of tissue injury and disease worsening (12).”
BackgroundInfluentialSARS-CoV-2–specific B- and T-cell immunity in a population-based study of young Swedish adults
Björkander, S., Du, L., Zuo, F., Ekström, S., Wang, Y., Wan, H., Sherina, N., Schoutens, L., Andréll, J., Andersson, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.014 · Cited by 53
“A connection between mild symptoms and lower T-cell responses has been suggested,(20) while other studies have failed to find this association,(4,5,22) and we and others have shown that specific T-cell responses are similar in symptomatic and asymptomatic subjects.(25,26) Furthermore, IgG titers were significantly hig…”
ResultChaurasia, P., Nguyen, T. H. O., Rowntree, L. C., Juno, J. A., Wheatley, A. K., Kent, S. J., Kedzierska, K., Rossjohn, J., & Petersen, J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101065 · Cited by 47
Elyanow, R., Snyder, T. M., Dalai, S. C., Gittelman, R. M., Boonyaratanakornkit, J. B., Wald, A., Selke, S., Wener, M. H., Morishima, C., Greninger, A. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.150070 · Cited by 51
“symptomatic cases compared with asymptomatic cases (40, 45, 46); thus, it is possible that sensitivity of TCR testing may be lower in individuals with asymptomatic disease.”
BackgroundSandberg, J. T., Varnaitė, R., Christ, W., Chen, P., Muvva, J. R., Maleki, K. T., García, M., Dzidic, M., Folkesson, E., Skagerberg, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1306 · Cited by 52
Heide, J., Schulte, S., Kohsar, M., Brehm, T. T., Herrmann, M., Karsten, H., Marget, M., Peine, S., Johansson, A. M., Sette, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009842 · Cited by 50
Vaccinating people who have had covid-19: why doesn’t natural immunity count in the US?
Block, J. (2021) · BMJ · doi:10.1136/bmj.n2101 · Cited by 55
Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children
Zhong, Y., Kang, A. Y. H., Tay, C. J. X., Li, H. E., Elyana, N., Tan, C. W., Yap, W. C., Lim, J. M. E., Bert, N. L., Chan, K. R., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02962-3 · Cited by 48
“The results obtained from the UMAP analysis were incorporated as additional parameters and converted to FCS files, which were then loaded into FlowJo to generate heatmaps of cytokine secretion on the reduced dimensions 9,10 .”
Self-citationKeep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Chitsike, L., & Duerksen-Hughes, P. J. (2021) · Virology Journal · doi:10.1186/s12985-021-01624-x · Cited by 48
“However, some individuals will go on to develop more severe symptoms, likely due to successful immune evasion by the virus and/or delayed and impaired responses by their immune systems [9, 12, 13].”
BackgroundDhawan, M. K., Rabaan, A. A., Fawarah, M. M., Almuthree, S. A., Alsubki, R. A., Alfaraj, A. H., Mashraqi, M. M., Alshamrani, S., Abduljabbar, W. A., Alwashmi, A. S. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11010101 · Cited by 47
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication
Pan, P., Ge, W., Lei, Z., Luo, W. P., Liu, Y., Guan, Z., Chen, L., Yu, Z., Shen, M., Hu, D., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01459-8 · Cited by 44
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Cai, C., Gao, Y., Adamo, S., Rivera‐Ballesteros, O., Hansson, L., Österborg, A., Bergman, P., Sandberg, J. K., Ljunggren, H., Björkström, N. K., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adh0687 · Cited by 47
“These results indicate that spike-specific CD4 + T cells shift toward a proinflammatory IFNG + phenotype after vaccination against COVID-19.”
ResultSyenina, A., Gan, E. S., Toh, J. Z. N., de Alwis, R., Lin, L. Z., Tham, C. Y. L., Yee, J. X., Leong, Y. S., Sam, H., Cheong, C., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001643 · Cited by 49
Self-citationRapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
Schwarz, M. C., Torre, D., Lozano‐Ojalvo, D., Tan, A. T., Tabaglio, T., Mzoughi, S., Sánchez-Tarjuelo, R., Bert, N. L., Lim, J. M. E., Hatem, S., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01347-6 · Cited by 44
Self-citationSARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Diani, S., Leonardi, E. A., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., Bouslenko, Z., Natalini, D., Conti, S., Mantovani, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216272 · Cited by 44
Pieren, D. K. J., Kuguel, S. G., Rosado, J., Robles, A. G., Rey-Cano, J., Mancebo-Pérez, C., Esperalba, J., Falcó, V., Buzón, M. J., & Genescà, M. (2023) · Nature Communications · doi:10.1038/s41467-023-37559-w · Cited by 46
New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic
Carvajal, J. J., García-Castillo, V., Cuellar, S. V., Campillay-Véliz, C. P., Salazar‐Ardiles, C., Avellaneda, A. M., Muñoz, C. A., Retamal-Díaz, A. R., Bueno, S. M., González, P. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363572 · Cited by 51
Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
Kruse, M., Dark, C., Aspden, M., Cochrane, D., Competiello, R., Peltz, M., Torres, L., Wrighton-Smith, P., & Dudek, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.073 · Cited by 47
Eser, T. M., Baranov, O., Huth, M., Ahmed, M. I. M., Deák, F., Held, K., Lin, L., Pekayvaz, K., Leunig, A., Nicolai, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38020-8 · Cited by 46
Chatterjee, B., Sandhu, H. S., & Dixit, N. M. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010630 · Cited by 42
“To test our model, we sought datasets that included accurate estimates of the time of contracting the disease because the initial phases of the immune response were likely to be important in determining disease outcome; in asymptomatic individuals, this early response clears the infection [36].”
MethodSevere respiratory viral infections: T-cell functions diverging from immunity to inflammation
Yunis, J., Short, K. R., & Yu, D. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2022.12.008 · Cited by 52
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Tarke, A., Zhang, Y., Methot, N., Narowski, T. M., Phillips, E. J., Mallal, S. A., Frazier, A., Filaci, G., Weiskopf, D., Dan, J. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101088 · Cited by 44
“SARS-CoV2-specific T cells were also able to cross-recognize other human CoVs, including SARS-CoV-1 and MERS-CoV, and other viral species.(29,45,46) Based on these data, it has been proposed that immunodominant T cell regions conserved across CoVs may be of interest for inducing a pan-CoV T cell response,(1) to be con…”
SARS-CoV-2 immunity in animal models
Chen, Z., Yuan, Y., Hu, Q., Zhu, A., Chen, F., Li, S., Guan, X., Lv, C., Tang, T., He, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01122-w · Cited by 43
Schanoski, A. S., Sauerwald, N., Goforth, C. W., Periasamy, S., Weir, D. L., Lizewski, S. E., Lizewski, R. A., Ge, Y., Kuzmina, N. A., Nair, V. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821730 · Cited by 41
“On the other hand, we also learned from elegant studies that asymptomatic individuals are able to mount an efficient memory T cell response against SARS-CoV-2 during the convalescent phase (14, 15).”
BackgroundSARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
Παπαδοπούλου, Α., Karavalakis, G., Papadopoulou, E., Xochelli, A., Bousiou, Z., Vogiatzoglou, A., Papayanni, P. G., Georgakopoulou, A., Giannaki, M., Stavridou, F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02480-8 · Cited by 42
Aiello, A., Fard, S. N., & Goletti, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244556 · Cited by 41
Lin, J., Law, R., Korosec, C. S., Zhou, C. Y., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Matveev, V., Yue, F., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00509-22 · Cited by 38
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac404 · Cited by 44
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen, J., Fan, J., Zhao, Y., Jiang, D., Niu, Z., Zhang, Z., & Cao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159326 · Cited by 44
Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination
Karl, V., Hofmann, M., & Thimme, R. (2025) · Journal of Virology · doi:10.1128/jvi.01350-24 · Cited by 38
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomić, A., Skelly, D., Ogbe, A., O’Connor, D., Pace, M. J., Adland, E., Alexander, F., Ali, M., Allott, K., Ansari, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28898-1 · Cited by 37
Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
Baldwin, J., Piplani, S., Sakala, I. G., Honda‐Okubo, Y., Li, L., & Petrovsky, N. (2021) · Bioanalysis · doi:10.4155/bio-2021-0096 · Cited by 35
“Recently ELISPOT analysis on a large cohort of COVID-19 patients demonstrated that although frequency of SARS-CoV-2-specific T cells were similar between asymptomatic and symptomatic patients, asymptomatic individuals showed increased IFN-γ and IL-2 production [92].”
Qui, M., Bert, N. L., Chan, W. P. W., Tan, M. T. K., Hang, S. K., Hariharaputran, S., Sim, J. X. Y., Low, J. G. H., Ng, W., Wan, W. Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159500 · Cited by 33
“There are some limitations to this study — the most important of these being that the bulk of T cell experiments were performed not by direct measurement of T cell quantity, but by measuring the T cell response detected in patients who control SARS-CoV-2 infection asymptomatically (28).”
Self-citationChildren and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Kaaijk, P., Pimentel, V. O., Emmelot, M. E., Poelen, M. C. M., Çevirgel, A., Schepp, R. M., den Hartog, G., Reukers, D. F. M., Beckers, L., van Beek, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817876 · Cited by 36
“Although, other studies showed a clear decline of the T cell response over a 6-8 month period in asymptomatic as well as symptomatic COVID-19 patients (35, 36).”
ResultTaus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 34
“found that responses against matrix were most targeted, followed by those against spike or nucleocapsid (envelope was not tested) (14), but Peng et al.”
BackgroundSARS-CoV-2 and male infertility: from short- to long-term impacts
Dai, P., Qiao, F., Chen, Y.-S. E., Chan, D. Y. L., Yim, H. C. H., Fok, K. L., & Chen, H. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02055-x · Cited by 33
Binayke, A., Zaheer, A., Vishwakarma, S., Singh, S., Sharma, P., Chandwaskar, R., Gosain, M., Raghavan, S., Murugesan, D. R., Kshetrapal, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00794-9 · Cited by 31
CD8+ T-cell immune escape by SARS-CoV-2 variants of concern
Kombe, A. J. K., Biteghe, F. A. N., Ndoutoume, Z. N., & Jin, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962079 · Cited by 30
“, a low titer of CD8 T-cells), suggesting that functional CD8 T-cells, but better associated with CD4 T-cells in SARS-CoV-2 infection, are therefore required for preventing infection severity associated with a better viral clearance (24, 25, 28, 29, 53, 88).”
BackgroundIlari, S., Proietti, S., Russo, P., Malafoglia, V., Gliozzi, M., Maiuolo, J., Oppedisano, F., Palma, E., Tomino, C., Fini, M., et al. (2022) · Antioxidants · doi:10.3390/antiox11122361 · Cited by 31
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice
Alves, R. P. D. S., Timis, J., Miller, R., Valentine, K. M., Pinto, P. B. A., Gonzalez, A., Regla-Nava, J. Á., Maule, E., Nguyen, M. N., Shafee, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45043-2 · Cited by 31
“…robust pre-existing HCoV/SARS-CoV-2 cross-reactive T cell responses that are rapidly induced following SARS-CoV-2 exposure have been associated with asymptomatic infection and less severe COVID-19, suggesting a role for these cells in protective immunity to SARS-CoV-2 23,29,39,41,81,119 .”
Lehmann, A. A., Kirchenbaum, G. A., Zhang, T., Reche, P. A., & Lehmann, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635942 · Cited by 34
Metadata
- Authors
- Le Bert, N., Clapham, H. E., Tan, A. T., Chia, W. N., Tham, C. Y. L., Lim, J. M., Kunasegaran, K., Tan, L. W. L., Dutertre, C.-A., Shankar, N., Lim, J. M. E., Sun, L. J., Zahari, M., Tun, Z. M., Kumar, V., Lim, B. L., Lim, S. H., Chia, A., Tan, Y.-J., Tambyah, P. A., Kalimuddin, S., Lye, D., Low, J. G. H., Wang, L.-F., Wan, W. Y., Hsu, L. Y., Bertoletti, A., & Tam, C. C.
- Affiliations
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 1
- National University of Singapore (SG)
- Inserm (FR)
- Alexandra Hospital (SG)
- Singapore General Hospital (SG)
- Agency for Science, Technology and Research (SG)
- National University Hospital (SG)
- Corresponding author
- Bertoletti, Antonio
- ORCID
- Le Bert, Nina
- Clapham, Hannah E.
- Tan, Anthony T.
- Chia, Wan Ni
- Tham, Christine Y.L.
- Lim, Jane M.
- Kunasegaran, Kamini
- Tan, Linda Wei Lin
- Dutertre, Charles-Antoine
- Shankar, Nivedita
- Lim, Joey M.E.
- Sun, Louisa Jin
- Zahari, Marina
- Tun, Zaw Myo
- Kumar, Vishakha
- Lim, Beng Lee
- Lim, Siew Hoon
- Chia, Adeline
- Tan, Yee-Joo
- Tambyah, Paul Anantharajah
- Kalimuddin, Shirin
- Lye, David
- Low, Jenny G.H.
- Wang, Lin-Fa
- Wan, Wei Yee
- Hsu, Li Yang
- Bertoletti, Antonio
- Tam, Clarence C.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-03-01
- Volume
- 218
- Issue
- 5
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7927662
- OpenAlex
- W3134489892
- Cited by
- 330
- References
- 38
- Citations by year
- 2026: 11 · 2025: 22 · 2024: 45 · 2023: 68 · 2022: 110 · 2021: 74
- FWCI
- 23.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- National University Health System (NUHSRO/2020/052/RO5+5/NUHS-COVID/6)
- Saw Swee Hock School of Public Health
- National University of Singapore
- National Research Foundation Singapore (NRF2016NRF-NSFC002-013)
- National Medical Research Council
- Ministry of Health - Singapore (STPRG-FY19-001, COVID19RF-003, COVID19RF3-0060)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- SARS-CoV-2, COVID-19 pandemic, asymptomatic infection, virus-specific T cells, cell-mediated immunity, interferon-gamma, interleukin-2, IL-10, inflammatory cytokines, cytokine production, spike protein, nucleocapsid protein, matrix protein, T cell activation, seroconversion
- MeSH terms
- COVID-19, SARS-CoV-2, Adult, Humans, Lymphocyte Activation, Male, Middle Aged, T-Lymphocytes, Cytokines, Asymptomatic Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.